13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
155 檔
22.9%
In Q1 2026, Bellevue Group AG's U.S. equity holdings reached a combined market value of $4.8B, distributed across 155 disclosed stock positions.
In Q1 2026, Bellevue Group AG adopted a defensive or profit-taking posture, trimming 87 positions and completely liquidating 40 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including VRTX, ARGX, REGN) accounted for 22.9% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 7.25% | -1.20% | +0.12% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.44% | +0.44% | -32.23% | |
| 3 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 5.12% | -3.06% | +1900.82% | |
| 4 | SRRK | Scholar Rock Holding CORP | Stock-Other | 4.19% | -1.36% | -11.64% | |
| 5 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.88% | +1.86% | +2117.70% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.57% | +0.56% | -69.15% | |
| 7 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.25% | -1.63% | -62.13% | |
| 8 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.14% | -1.01% | -10.98% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.13% | -0.53% | +54.32% | |
| 10 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.96% | -2.35% | +17.42% | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.84% | -0.78% | +81088.12% | |
| 12 | ABT | Abbott Laboratories | Stock-Healthcare | 2.81% | -1.00% | -12.55% | |
| 13 | NUVL | Nuvalent Inc-a | Stock-Other | 2.57% | +0.17% | +1.52% | |
| 14 | AMGN | Amgen Inc | Stock-Healthcare | 2.47% | +4.02% | +1497.48% | |
| 15 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.19% | -1.39% | -5.94% | |
| 16 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.17% | -0.58% | — | |
| 17 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.01% | -0.15% | — | |
| 18 | MDT | Medtronic plc | Stock-Healthcare | 1.97% | -0.33% | +24.88% | |
| 19 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.85% | -1.84% | -47.40% | |
| 20 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.85% | +0.59% | -6.59% | |
| 21 | SYK | Stryker CORP | Stock-Healthcare | 1.70% | +0.08% | -39.75% | |
| 22 | PCVX | Vaxcyte Inc | Stock-Other | 1.65% | +0.76% | — | |
| 23 | VERA | Vera Therapeutics Inc | Stock-Other | 1.64% | -0.10% | +0.74% | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.60% | -0.19% | -19.52% | |
| 25 | DMRA | Damora Therapeutics Inc | Stock-Other | 1.42% | -0.53% | — | |
| 26 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.19% | -0.73% | -38.90% | |
| 27 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 1.19% | -0.51% | -5.72% | |
| 28 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.19% | +0.20% | +92148.06% | |
| 29 | DXCM | Dexcom Inc | Stock-Healthcare | 1.18% | -0.01% | -6.92% | |
| 30 | JBIO | Jade Biosciences Inc | Stock-Other | 1.17% | +0.26% | +4.80% | |
| 31 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.15% | -1.15% | EXIT | |
| 32 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.95% | +0.35% | -15.39% | |
| 33 | DHR | Danaher CORP | Stock-Healthcare | 0.91% | -0.33% | +3.87% | |
| 34 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.91% | +0.03% | -66.83% | |
| 35 | RMD | Resmed Inc | Stock-Healthcare | 0.85% | -0.24% | -1.16% | |
| 36 | PODD | Insulet CORP | Stock-Healthcare | 0.82% | -0.41% | -12.34% | |
| 37 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.75% | +0.09% | -1.02% | |
| 38 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.74% | +0.01% | -0.21% | |
| 39 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.71% | -0.37% | -1.80% | |
| 40 | IRON | Disc Medicine Inc | Stock-Other | 0.70% | +0.16% | — | |
| 41 | JNJ | Johnson & Johnson | Stock-Healthcare | 0.69% | -0.14% | -6.07% | |
| 42 | ANNX | Annexon Inc | Stock-Other | 0.68% | -0.19% | — | |
| 43 | CI | THE Cigna Group | Stock-Healthcare | 0.62% | -0.23% | -10.68% | |
| 44 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.59% | +2.73% | — | |
| 45 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.59% | -0.28% | +124.27% | |
| 46 | ALGN | Align Technology Inc | Stock-Healthcare | 0.57% | -0.07% | -1.27% | |
| 47 | STE | STERIS plc | Stock-Healthcare | 0.53% | -0.09% | -1.80% | |
| 48 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.51% | -0.27% | -5.87% | |
| 49 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.49% | +0.12% | — | |
| 50 | ABBV | Abbvie Inc | Stock-Healthcare | 0.48% | -0.27% | -30.62% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | REGN | Regeneron Pharmaceuticals | +4.9% | +1900.82% | Add |
| 2 | GILD | Gilead Sciences Inc | +3.8% | +2117.70% | Add |
| 3 | CRNX | Crinetics Pharmaceuticals In | +2.8% | +81088.12% | Add |
| 4 | AMGN | Amgen Inc | +2.4% | +1497.48% | Add |
| 5 | VRTX | Vertex Pharmaceuticals Inc | +1.4% | +0.12% | Add |
| 6 | RARE | Ultragenyx Pharmaceutical In | +1.2% | +92148.06% | Add |
| 7 | KRYS | Krystal Biotech Inc | +1% | +17.42% | Add |
| 8 | SRRK | Scholar Rock Holding CORP | +0.8% | -11.64% | Trim |
| 9 | NUVL | Nuvalent Inc-a | +0.6% | +1.52% | Add |
| 10 | MDT | Medtronic plc | +0.6% | +24.88% | Add |
| 11 | VRDN | Viridian Therapeutics Inc | +0.6% | +54.32% | Add |
| 12 | TNGX | Tango Therapeutics Inc | +0.5% | -38.90% | Trim |
| 13 | RLAY | Relay Therapeutics Inc | +0.5% | -6.59% | Trim |
| 14 | EWTX | Edgewise Therapeutics Inc | +0.4% | — | Unchanged |
| 15 | MRK | Merck & Co. Inc. | +0.4% | +124.27% | Add |
| 16 | JNJ | Johnson & Johnson | +0.2% | -6.07% | Trim |
| 17 | ANNX | Annexon Inc | +0.2% | — | Unchanged |
| 18 | JBIO | Jade Biosciences Inc | +0.2% | +4.80% | Add |
| 19 | IMCR | Immunocore Holdings Plc-adr | +0.2% | — | Unchanged |
| 20 | ALGN | Align Technology Inc | +0.2% | -1.27% | Trim |
| 21 | DXCM | Dexcom Inc | +0.1% | -6.92% | Trim |
| 22 | RMD | Resmed Inc | +0.1% | -1.16% | Trim |
| 23 | GMED | Globus Medical Inc - A | +0.1% | -5.87% | Trim |
| 24 | DHR | Danaher CORP | +0.1% | +3.87% | Add |
| 25 | TXG | 10x Genomics Inc-class A | +0.1% | +2.31% | Add |
| 26 | MCK | Mckesson CORP | +0.1% | -10.94% | Trim |
| 27 | LLY | Eli Lilly & Co | +0.1% | -0.21% | Trim |
| 28 | GEHC | GE Healthcare Technology | +0.1% | -1.80% | Trim |
| 29 | CI | THE Cigna Group | +0.1% | -10.68% | Trim |
| 30 | MDLN | Medline Inc-cl A | +0.1% | +16.07% | Add |
| 31 | TMO | Thermo Fisher Scientific Inc | 0% | -1.02% | Trim |
| 32 | STE | STERIS plc | 0% | -1.80% | Trim |
| 33 | HCA | Hca Healthcare Inc | 0% | -13.99% | Trim |
| 34 | PFE | Pfizer Inc | 0% | +89.34% | Add |
| 35 | RPRX | Royalty Pharma plc | 0% | +190.10% | Add |
| 36 | THC | Tenet Healthcare CORP | 0% | -4.90% | Trim |
| 37 | ONC | Beone Medicines Ltd-adr | 0% | +101.69% | Add |
| 38 | VERA | Vera Therapeutics Inc | 0% | +0.74% | Add |
| 39 | COO | Cooper Cos Inc/the | 0% | -6.77% | Trim |
| 40 | TMDX | Transmedics Group Inc | 0% | +3.32% | Add |
| 41 | COR | Cencora Inc | 0% | +229.37% | Add |
| 42 | DNLI | Denali Therapeutics Inc | 0% | +148.89% | Add |
| 43 | OLMA | Olema Pharmaceuticals Inc | 0% | +321.40% | Add |
| 44 | CRSP | CRISPR Therapeutics AG | 0% | +166.81% | Add |
| 45 | ALKS | Alkermes plc | 0% | +34.52% | Add |
| 46 | TVTX | Travere Therapeutics Inc | 0% | +132.53% | Add |
| 47 | MDGL | Madrigal Pharmaceuticals Inc | 0% | +5.41% | Add |
| 48 | PTGX | Protagonist Therapeutics Inc | 0% | -12.67% | Trim |
| 49 | MLYS | Mineralys Therapeutics Inc | 0% | +48.16% | Add |
| 50 | SMMT | Summit Therapeutics Inc | 0% | +11.19% | Add |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 155 disclosed positions in Q1 2026.
During Q1 2026, Bellevue Group AG's top holdings by market value included VRTX (7.3%)、ARGX (5.4%)、REGN (5.1%). The largest single position, VRTX, represented 7.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ELVN
市值: $91.0M
Top Position Liquidated / Trimmed
RNAGBP
前期市值: $189.8M
In Q1 2026, Bellevue Group AG made 180 total portfolio adjustments, initiating 19 new buys, adding to 34 positions, trimming 87 holdings, and fully liquidating 40 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.